Advertisement
Medtronic
Subscribe to Medtronic
View Sample

FREE Email Newsletter

Medtronic Announces Approval and Launch of Japan’s First MR-Conditional Pacemaker System

October 18, 2012 12:32 pm | by Medtronic | News | Comments

Medtronic, Inc. (NYSE: MDT), today announced the Japanese regulatory approval and launch of the Advisa DR MRI™ SureScan™ pacing system. The Advisa MRI system is the first and only MR-Conditional pacemaker available to patients in Japan, the world’s second largest market for medical devices.

Medtronic reports first quarter earnings

August 23, 2012 6:09 am | by I-Micronews | News | Comments

The Company reported worldwide first quarter revenue of $4.008 billion, an increase of 5 percent on a constant currency basis after adjusting for a $119 million negative foreign currency impact or 2 percent as reported. As reported, first quarter net earnings were $864 million, or $0.83 per diluted share...

M&A: The top 15 acquirers among medical device companies

August 6, 2012 3:37 pm | by Mass Device | News | Comments

A look at the most acquisitive medical device companies, culled from MassDevice.com's Big 100 database of more than 1,300 medical device industry transactions. More than $50 billion was spent on acquisitions by Big 100 medical device companies from the beginning of 2011 through the 1st half of 2012.

Advertisement

Medtronic wins expanded FDA indication for snoring implant | Regulatory Roundup

July 12, 2012 10:29 am | by Mass Device | News | Comments

Medtronic touts expanded indication for up to 5 implants of its Pillar Palatal devices to treat snoring.  Medtronic obtains expanded indication for snoring treatment system...

Medtronic's Ishrak lands $25M in salary, benefits in 1st year

July 2, 2012 8:30 am | by Mass Device | News | Comments

Medtronic CEO Omar Ishrak's 1st-year take-home tops $25 million in salary, stock and bonuses that made up for benefits he gave up to take the job. MASSDEVICE ON CALL —Medtronic (NYSE:MDT) CEO Omar Ishrak's first year on the job netted him more than $25 million in salary, stock and bonuses that helped make up for the benefits he forfeited in order to take the jobs. Legal News, News Well, Healthcare Reform, On Call, Venture Capital/Private Equityread more

Medtronic Launches Endurant II AAA Stent Graft System in U.S.

June 7, 2012 7:55 am | News | Comments

Medtronic, Inc. has announced the U.S. launch of the Endurant® II AAA Stent Graft System, which recently received approval from the U.S. Food and Drug Administration (FDA) for the minimally invasive treatment of abdominal aortic aneurysms through endovascular repair...

Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe

May 15, 2012 11:57 am | News | Comments

As EuroPCR 2012 gets under way today, Medtronic, Inc. announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications, making it the drug-eluting stent (DES) with the broadest range of approved indications...

Medtronic Named One of America's Best Corporate Citizens

April 25, 2012 5:38 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. is one of America's best corporate citizens, according to the rankings recently released by Corporate Responsibility magazine. Medtronic made the top 50 list, moving up 16 spots from its 66th ranking in 2011.

Advertisement

Medtronic Initiates Landmark U.S. Drug-Eluting Balloon Study

April 13, 2012 7:19 am | News | Comments

MINNEAPOLIS –– Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic, Inc. announced today the start of the Medtronic IN.PACT SFA II study, the company’s first...

Medtronic Reaches Settlement of Shareholder Class Action

April 2, 2012 5:26 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. today announced that the company has reached an agreement in principle to settle a previously disclosed federal securities class action. Under the settlement, the company will make a payment of $85 million to resolve all of the class claims.

Medtronic Receives CE Mark for Pacemaker Lead That Will Expand Patient Access to MRI Technology

March 6, 2012 4:54 am | News | Comments

Medtronic, Inc. today announced the receipt of CE Mark (Conformité Européenne) and launch of the CapSure Sense MRI™ SureScan® pacing leads, which are approved for use during Magnetic Resonance Imaging (MRI). Medtronic introduced the first MR-Conditional pacemaker system in the world in 2008 and in the U.S. in 2011.

Medtronic Stent Resulted in 90% Freedom from Reinterventions in Narrowed Leg Arteries at 12 Months in International Study

February 9, 2012 5:09 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Consistent with its commitment to developing better treatments for peripheral arterial disease (PAD), Medtronic Inc. today announced the one-year results of an international study of the Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis...

Medtronic Announces First Patient Enrollment in Clinical Trial Assessing Guideline-Based Heart Failure Management in Primary Care Setting

February 2, 2012 5:12 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. today announced the initiation and first patient enrollment in a clinical study that will evaluate gaps in the implementation of evidence-based treatment guidelines among chronic heart failure patients post-hospital discharge.

Advertisement

Valley Presbyterian Hospital Site for First Use of New Heart Device in U.S. since FDA Approval

February 1, 2012 5:51 am | News | Comments

VAN NUYS, Calif.--(BUSINESS WIRE)--Valley Presbyterian Hospital (VPH) was the site for the first implantation in the U.S. of a new heart device since the Food and Drug Administration (FDA) approved the DF4 High-Voltage Connector System by Medtronic earlier this month...

Medtronic Announces FDA Approval of DF4 High-Voltage Connector System for Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Devices

January 31, 2012 5:59 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac...

Medtronic Launches New Minimally Invasive Cardiac Surgery Products Through Exclusive Distribution Agreement with Miami Instruments

January 30, 2012 5:50 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC – a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery (MICS) procedures...

Medtronic Completes Enrollment of Extreme Risk Patient Group in CoreValve U.S. Pivotal Trial

January 25, 2012 5:50 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The company also received approval from the U.S. Food and Drug Administration (FDA) for an extended investigation...

First Patient Enrolled in Medtronic-Supported Head-to-Head Clinical Trial Comparing Cryoballoon Ablation to RF Ablation for Paroxysmal Atrial Fibrillation

January 25, 2012 5:46 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized, multinational head-to-head clinical trial comparing the long-term safety, effectiveness and ease of use of the Medtronic Arctic...

Medtronic Announces 510(k) Clearance for the Aquamantys SBS 5.0 Sheathed Bipolar Sealer for Spine Surgery

January 24, 2012 4:44 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS 5.0 Sheathed Bipolar Sealer, a new addition to the spine portfolio of the company's Advanced Energy business.

Medtronic Launches First-of-Its-Kind mySentry Remote Glucose Monitor

January 5, 2012 5:12 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Today, Medtronic, Inc. announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind mySentryâ„¢ Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient's MiniMed...

Data Shows Medtronic AdaptiveStim with RestoreSensor Provides Pain Relief and Convenience

December 12, 2011 4:51 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Clinical trial data presented at the 15th Annual Meeting of the North American Neuromodulation Society demonstrate the AdaptiveStimâ„¢ with RestoreSensorâ„¢ neurostimulation system from Medtronic provides clinical benefits for many patients...

FDA Advisory Panel Recommends Expanded Indication for Medtronic Cardiac Resynchronization Therapy with Defibrillator (CRT-D) Devices

December 9, 2011 5:35 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices Advisory Panel determined that the overall clinical benefits of Medtronic cardiac resynchronization therapy...

Medtronic Receives FDA Approval for Next Generation Professional Continuous Glucose Monitoring

November 23, 2011 6:11 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced the Food and Drug Administration (FDA) approval of iPro®2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals...

Medtronic Receives FDA Approval of Adaptivestim with Restoresensor for the Management of Chronic Pain

November 23, 2011 5:59 am | News | Comments

MINNEAPOLIS – November 17, 2011 – Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food & Drug Administration (FDA) approval of its AdaptiveStim™ with RestoreSensor™ neurostimulation system, the first and only chronic pain treatment that harnesses motion sensor technology...

Retrospective Study Shows New Device Significantly Reduces Blood Loss and Transfusions in Adolescent Scoliosis Corrective Surgery

November 10, 2011 5:45 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today reported results of an retrospective study available online and in an upcoming print edition of the Journal of Spinal Disorders and Techniques that demonstrates the effectiveness of the Aquamantys® System...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading